WASHINGTON (dpa-AFX) - Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, Tuesday said it has been granted Orphan Drug Designation for SLS-005 in mucopolysaccharidosis type III, Sanfilippo syndrome, from the European Medicines Agency.
To date, SLS-005 has been granted Orphan Drug Designation in the US and Europe for Sanfilippo syndrome, Spinocerebellar Ataxia Type 3 and Oculopharyngeal Muscular Dystrophy as well as Fast Track designation for OPMD.
Copyright RTT News/dpa-AFX